{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:13:37Z","timestamp":1780056817416,"version":"3.54.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"52","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,2]],"date-time":"2016-11-02T00:00:00Z","timestamp":1478044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.vaccine.2016.10.079","type":"journal-article","created":{"date-parts":[[2016,11,22]],"date-time":"2016-11-22T03:22:12Z","timestamp":1479784932000},"page":"6665-6671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Vaccine provision: Delivering sustained &amp; widespread use"],"prefix":"10.1016","volume":"34","author":[{"given":"Scott","family":"Preiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Gar\u00e7on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony L.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Strugnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard R.","family":"Friedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.10.079_b0005","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1080\/21645515.2015.1043501","article-title":"Safety assessment of adjuvanted vaccines: methodological considerations","volume":"11","author":"Da Silva","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2016.10.079_b0010","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1542\/peds.2010-1722E","article-title":"Food and Drug Administration regulation and evaluation of vaccines","volume":"127","author":"Marshall","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2016.10.079_b0015","unstructured":"Good Clinical Practice:ICH. May 1996 n.d. <http:\/\/www.ich.org\/products\/guidelines\/efficacy\/efficacy-single\/article\/good-clinical-practice.html> [accessed May 23, 2016]."},{"issue":"3","key":"10.1016\/j.vaccine.2016.10.079_b0020","first-page":"320","article-title":"Vaccine Adjuvants: from 1920 to 2015 and Beyond","volume":"2015","author":"Di Pasquale","year":"1920","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2016.10.079_b0025","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1586\/14760584.2014.959931","article-title":"Strategies for continuous evaluation of the benefit-risk profile of HPV-16\/18-AS04-adjuvanted vaccine","volume":"13","author":"Angelo","year":"2014","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.10.079_b0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1586\/14760584.8.2.227","article-title":"Quality-control issues and approaches in vaccine development","volume":"8","author":"Metz","year":"2009","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.10.079_b0035","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.biologicals.2014.05.007","article-title":"Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies","volume":"42","author":"Kumru","year":"2014","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2016.10.079_b0080","series-title":"Vaccines","first-page":"44","article-title":"Vaccine Manufacturing","author":"Gomez","year":"2013"},{"key":"10.1016\/j.vaccine.2016.10.079_b0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/2051013615611017","article-title":"Clinical development of Ebola vaccines","volume":"3","author":"Sridhar","year":"2015","journal-title":"Ther Adv Vaccines"},{"key":"10.1016\/j.vaccine.2016.10.079_b0045","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1542\/peds.2014-4015","article-title":"First use of a serogroup B meningococcal vaccine in the us in response to a university outbreak","volume":"135","author":"McNamara","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2016.10.079_b0050","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.vaccine.2010.11.042","article-title":"Lessons from pandemic influenza A(H1N1): the research-based vaccine industry\u2019s perspective","volume":"29","author":"Abelin","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.079_b0085","series-title":"World on the verge of an effective Ebola vaccine","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.vaccine.2016.10.079_b0055","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1586\/14760584.2014.923761","article-title":"Tools and approaches to ensure quality of vaccines throughout the cold chain","volume":"13","author":"Kartoglu","year":"2014","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.10.079_b0060","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ypmed.2004.01.029","article-title":"Exposure of hepatitis B vaccine to freezing temperatures during transport to rural health centers in Mongolia","volume":"39","author":"Edstam","year":"2004","journal-title":"Prev Med"},{"key":"10.1016\/j.vaccine.2016.10.079_b0065","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0140-6736(04)15892-3","article-title":"Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines","volume":"363","author":"Webby","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.10.079_b0070","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12033-014-9837-y","article-title":"Carrot cells: a pioneering platform for biopharmaceuticals production","volume":"57","author":"Rosales-Mendoza","year":"2015","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.vaccine.2016.10.079_b0075","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.tplants.2009.09.009","article-title":"Plant-made vaccine antigens and biopharmaceuticals","volume":"14","author":"Daniell","year":"2009","journal-title":"Trends Plant Sci"},{"key":"10.1016\/j.vaccine.2016.10.079_b0105","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1016\/j.vaccine.2016.10.016","article-title":"Vaccine development: From concept to early clinical testing","volume":"34","author":"Cunningham","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.079_b0095","doi-asserted-by":"crossref","first-page":"6672","DOI":"10.1016\/j.vaccine.2016.10.039","article-title":"Vaccine safety evaluation: Practical aspects in assessing benefits and risks","volume":"34","author":"Di Pasquale","year":"2016","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16310313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16310313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T17:01:01Z","timestamp":1537549261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16310313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":19,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0264410X16310313"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.079","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine provision: Delivering sustained & widespread use","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}